Drug Profile
Thrombopoietin gene therapy - Bioenvision
Alternative Names: TPO gene therapyLatest Information Update: 07 Feb 2017
Price :
$50
*
At a glance
- Originator Bioenvision
- Class
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 06 Feb 2017 Discontinued - Phase-I for Thrombocytopenia in USA (Parenteral)
- 30 Jun 2006 Suspended - Phase-I for Thrombocytopenia in USA (Parenteral)
- 29 Oct 2003 Phase-I clinical trials in Thrombocytopenia in USA (Parenteral)